CureVac Stock Ceases Trading Following BioNTech Acquisition

The CureVac share has officially been delisted from public markets, marking the conclusion of its independent trading history. This final step comes after BioNTech successfully completed its full acquisition of the company. A critical deadline now approaches for former minority shareholders seeking to reclaim Dutch withholding tax.

Strategic Merger Finalizes Delisting

BioNTech finalized the post-offer restructuring on January 6, 2026, merging CureVac N.V. into CureVac Merger B.V. This gave BioNTech complete ownership of all operational activities. Subsequently, the formal delisting from the Nasdaq exchange occurred on January 16, 2026, ending all public trading.

Key transaction details include:
* Total Consideration: Approximately $1.25 billion, paid in BioNTech shares
* Tender Acceptance: 86.75% of CureVac shares were tendered into the offer
* Shares Acquired: 195,341,219 CureVac shares
* Final Trading Price: $4.66 per share

The ticker symbol “CVAC” has been retired, and no freely tradable CureVac shares remain.

Urgent Tax Reclaim Deadline for Investors

Shareholders who did not tender their shares during the initial offer received identical compensation through a mandatory squeeze-out procedure. However, this payout was subject to Dutch dividend withholding tax.

• Statutory Withholding Rate: 15%
• Effectively Applied Rate: 3.01% (accounting for recognized capital)

Non-resident investors of the Netherlands may be eligible to reclaim this withheld tax, either in full or in part. The submission deadline for such reclaim applications is January 27, 2026. Affected former CureVac shareholders must contact BioNTech directly at curevac-withholdingtax@biontech.com.

Applications received after this date cannot be processed under current regulations.

Should investors sell immediately? Or is it worth buying CureVac?

Leadership and Operational Integration

The previous CureVac management team has resigned en masse. A new supervisory board for CureVac SE has been appointed, consisting entirely of BioNTech leadership:
* Prof. Ugur Sahin (CEO of BioNTech)
* Sierk Poetting
* Ramón Zapata-Gomez

This move underscores the full operational integration of CureVac’s assets into BioNTech’s corporate framework.

SEC Deregistration Process Underway

Concurrent with the Nasdaq delisting, CureVac has filed a Form 25 with the U.S. Securities and Exchange Commission (SEC) to initiate the formal delisting and deregistration of its shares. A subsequent Form 15 will terminate all ongoing reporting obligations to the SEC.

The complete deregistration is expected to take effect approximately 90 days after the initial filing, concluding the administrative dissolution of CureVac as a publicly listed U.S. reporting company.

Uniting mRNA Platforms Under One Roof

The acquisition consolidates two pioneering German mRNA firms. As part of the deal, BioNTech gains control of several key CureVac assets:
* Proprietary mRNA design and delivery technologies
* The “RNA Printer” production platform
* Oncology programs, including CVGBM for glioblastoma
* Manufacturing facilities in Tübingen
* A full settlement of all prior patent disputes between the entities

In a related development, Goldman Sachs upgraded BioNTech to a “Buy” rating on January 17, 2026. The investment bank cited the strengthened oncology pipeline and the strategic value of the combined mRNA platforms as primary reasons for the upgrade.

Investment Implications Shift to BioNTech

For investors, the transaction has a clear consequence: any future economic impact from CureVac’s technologies and research programs will be reflected solely in the share performance of BioNTech. Within the German mRNA sector, BioNTech now stands as the dominant entity, consolidating the technological resources and product pipelines of both organizations.